5 Stocks in the News to Watch Now: LGVN, PRSO, SIR
Post# of 37040
(Total Views: 76)
Posted On: 07/22/2024 12:41:18 PM
5 Stocks in the News to Watch Now: LGVN, PRSO, SIRI, INBS, VTAK
https://www.marketscreener.com/quote/stock/LO...-47432541/
Longeveron Inc. (NASDAQ: LGVN) announced in July 2024 that the FDA granted Fast Track designation for its cellular therapy, Lomecel-B(TM), aimed at treating mild Alzheimer's Disease, accelerating its clinical development. The therapy also received RMAT designation, and the company announced a $9 million registered direct offering managed by H.C. Wainwright & Co.
Peraso Inc. (NASDAQ: PRSO) a leader in mmWave technology for 5G and 60 GHz networks, announced preliminary Q2 revenues of approximately $4.2 million, ending June 30, 2024, exceeding prior guidance. This represents a 50% sequential and 70% year-on-year growth. The stock has been trending upward, with investors anticipating it may rise above the 200 DMA and potentially challenge its three-month high of $2.04.
SiriusXM (NASDAQ: SIRI) reported year-on-year revenues at $2.16 billion, beating analysts' forecasts by 1.4%. The stock has surged from a multiyear low in the past month, likely due to a short squeeze ahead of its anticipated merger with Liberty Sirius XM Holdings, Read more.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) announced in July 2024, 3 new UK major manufacturers, have adopted its "Fingerprint Drug Screening System" for fast, reliable drug detection from fingertip sweat. Additionally, the system's successful biocompatibility testing advances it toward FDA 510(k) clearance, aiming for US market entry in 2025.
Catheter Precision (NYSE American: VTAK) implemented a new share structure on July 15, 2024, ensuring equal impact on shareholders. The company received evaluations and orders for its LockeT product from institutions such as UCLA Ronald Reagan Medical Center and HCA Healthcare. Their expansion strategy involves first introducing LockeT products to establish credibility, followed by the rollout of VIVO products. Additionally, the patient follow-up phase for the VIVO European Registry concluded in June 2023.
https://www.marketscreener.com/quote/stock/LO...-47432541/
Longeveron Inc. (NASDAQ: LGVN) announced in July 2024 that the FDA granted Fast Track designation for its cellular therapy, Lomecel-B(TM), aimed at treating mild Alzheimer's Disease, accelerating its clinical development. The therapy also received RMAT designation, and the company announced a $9 million registered direct offering managed by H.C. Wainwright & Co.
Peraso Inc. (NASDAQ: PRSO) a leader in mmWave technology for 5G and 60 GHz networks, announced preliminary Q2 revenues of approximately $4.2 million, ending June 30, 2024, exceeding prior guidance. This represents a 50% sequential and 70% year-on-year growth. The stock has been trending upward, with investors anticipating it may rise above the 200 DMA and potentially challenge its three-month high of $2.04.
SiriusXM (NASDAQ: SIRI) reported year-on-year revenues at $2.16 billion, beating analysts' forecasts by 1.4%. The stock has surged from a multiyear low in the past month, likely due to a short squeeze ahead of its anticipated merger with Liberty Sirius XM Holdings, Read more.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) announced in July 2024, 3 new UK major manufacturers, have adopted its "Fingerprint Drug Screening System" for fast, reliable drug detection from fingertip sweat. Additionally, the system's successful biocompatibility testing advances it toward FDA 510(k) clearance, aiming for US market entry in 2025.
Catheter Precision (NYSE American: VTAK) implemented a new share structure on July 15, 2024, ensuring equal impact on shareholders. The company received evaluations and orders for its LockeT product from institutions such as UCLA Ronald Reagan Medical Center and HCA Healthcare. Their expansion strategy involves first introducing LockeT products to establish credibility, followed by the rollout of VIVO products. Additionally, the patient follow-up phase for the VIVO European Registry concluded in June 2023.
(0)
(0)Scroll down for more posts ▼